This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
April 2025 in “International Journal of Molecular Sciences” This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
May 2025 in “International Journal of Applied Pharmaceutics” This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.
